American Society of Nephrology Kidney Week Glomerular Diseases 2024 Update

Glomerular medicine is exploding with exciting new understanding of disease pathogenesis, which has led to developments in novel genetic and serological diagnostic tools, clinical trials, and potential treatments. This program explores novel changes in IgAN/Henoch-Schonlein purpura, lupus nephritis, podocytopathies (FSGS/minimal change disease), membranous GN, atypical hemolytic uremic syndrome/C3 glomerulopathy, diabetic kidney disease, glomerular disease as “CKD,” and monoclonal gammopathy of renal significance. Hot topics are reviewed, including how and when to use genetics in the diagnosis and treatment of glomerular diseases, chimeric antigen receptor T cell therapy, balancing cost and efficacy of new medications for glomerular diseases, and precision medicine and clinical trials. Experts present cutting-edge clinical applications in treatment, pathology, and genetics that continue to change the diagnostic and therapeutic landscape in glomerular diseases.

The American Society of Nephrology (ASN) Kidney Week 2024 will feature a session titled “Glomerular Diseases: 2024 Update.” This session will explore exciting new developments in the understanding of disease pathogenesis, novel genetic and serological diagnostic tools, clinical trials, and potential treatments for glomerular diseases. Topics covered will include:

• IgA Nephropathy (IgAN) / Henoch-Schonlein purpura
• Lupus nephritis
• Podocytopathies (FSGS / minimal change disease)
• Membranous glomerulonephritis (GN)
• Atypical hemolytic uremic syndrome / C3 glomerulopathy
• Diabetic kidney disease
• Glomerular disease as “CKD”
• Monoclonal gammopathy of renal significance

The session will also review hot topics such as the use of genetics in diagnosis and treatment, chimeric antigen receptor T cell therapy, balancing cost and efficacy of new medications, and precision medicine and clinical trials